角膜疾病是我国第二位致盲原因，而角膜移植是许多致盲性角膜疾病唯一的治疗手段和最后的复明希望。然而，高危角膜移植术后的植片高排斥率一直是困扰眼科临床的难题。近十年来新兴的淋巴管研究为器官移植免疫学提供了新的研究方向。本研究的目的在于探讨淋巴管增生与高危角膜移植术后植片排斥反应的关系及其相关分子生物学机制。我们将模拟临床常见的高危角膜移植模型，追踪移植术后淋巴管相关因子以及淋巴管增生的变化规律，并探究抗淋巴管因子对高危角膜移植植片排斥反应的治疗效果。基于我们前期的研究结果，本研究将有望为揭开高危角膜移植术后高排斥反应的发生机制开创新的理念，并为其临床预防和治疗提供新的策略。此外，角膜淋巴管的研究也将为其它器官移植以及全身淋巴系统相关性疾病的发病机理及治疗提供新思路。

Corneal disease is the second major cause of blindness in our country, and corneal transplantation remains the only treatment of many blinding corneal diseases and the last hope for restoring vision. However, the high rejection rate after high-risk corneal transplantation has been a clinical dilemma. Lymphatic research, a novel field with rapid development during the past decade, brings a new research direction to the immunology related to organ transplantation. The purpose of current study is to investigate the relationship between lymphangiogenesis (the formation of new lymphatic vessels) and graft rejection after high-risk corneal transplantation. We plan to set up mouse models of high-risk corneal transplantation, follow the postoperative changes of lymphatic factors and lymphangiogenesis, and observe the therapeutic effect of anti-lymphangiogenesis drug after high-risk corneal transplantation. Based on our previous results, we anticipate that the current study can provide new concept to the pathological mechanism on high graft rejection after high-risk corneal transplantation, and provide a new strategy to treat this clinical condition. Additionally, the current study will also benefit the research and treatment of other organ transplantation and systemic lymphatic diseases.